Related references
Note: Only part of the references are listed.Twelve Hundred Consecutive Pancreato-Duodenectomies from Single Centre: Impact of Centre of Excellence on Pancreatic Cancer Surgery Across India
Shailesh V. Shrikhande et al.
WORLD JOURNAL OF SURGERY (2020)
Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms
Stefano Partelli et al.
SURGERY (2018)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
Rodney J. Hicks et al.
NEUROENDOCRINOLOGY (2017)
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials
Mauro Cives et al.
CURRENT OPINION IN ONCOLOGY (2016)
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate
Esther I. van Vliet et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Defining Borderline Resectable Pancreatic Cancer: Emerging Consensus for an Old Challenge
Mokenge P. Malafa
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
GEP-NETS UPDATE Radionuclide therapy in neuroendocrine tumors
Wouter A. van der Zwan et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options
K. E. Oberg
CLINICAL ONCOLOGY (2012)
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable
T. W. Barber et al.
EJSO (2012)
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
Anna Sowa-Staszczak et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
Marialuisa Appetecchia et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor
Oliver Stoeltzing et al.
LANGENBECKS ARCHIVES OF SURGERY (2010)
Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease
A. Frilling et al.
BRITISH JOURNAL OF SURGERY (2009)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors - An institutional experience
Paulus G. Schurr et al.
ANNALS OF SURGERY (2007)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival
JM Sarmiento et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2003)
Share Paper
